ResMed Inc. ($RMD) Stock Forecast: Down 3.2% Today

What is ResMed Inc.?

ResMed Inc. (RMD) is a global leader in sleep apnea and respiratory care devices, with a strong market presence and a focus on digital health solutions. Today, the stock experienced a bearish movement.

Why is ResMed Inc. going down?

RMD stock is down 3.2% on Mar 25, 2026 14:36

• A downgrade from Buy to Hold may have influenced investor sentiment, leading to a sell-off of ResMed's shares.
• Despite maintaining a Buy rating and a positive outlook, the market might have reacted more strongly to the rating change.
• An increased stake by Nordea Investment Management indicates long-term confidence in ResMed but short-term market dynamics could have overshadowed this positive development.
• The FDA approval of LivaNova's aura6000 System for OSA treatment may have created some competition concerns among investors, impacting ResMed's stock performance negatively.

RMD Price Chart

RMD Technical Analysis

RMD News

Research Alert: CFRA Lowers Rating On Shares Of Resmed Inc. To Hold From Buy

CFRA has lowered its rating on ResMed Inc. shares from Buy to Hold. This change reflects CFRA's updated investment perspective on the company.

https://www.moomoo.com/news/post/67348475/research-alert-cfra-lowers-rating-on-shares-of-resmed-inc

Morgan Stanley Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $310

Morgan Stanley has reiterated its Buy rating on ResMed (RMD.US) and maintained its price target of $310. This indicates a continued positive outlook from the firm regarding ResMed's stock performance.

https://www.moomoo.com/news/post/67290672/morgan-stanley-maintains-resmed-rmdus-with-buy-rating-maintains-target

Nordea Investment Management Boosts ResMed Stake by 37%

Nordea Investment Management AB has significantly increased its stake in ResMed Inc. by 37.2% during the 4th quarter, now owning over 1 million shares valued at $262 million. This move signals Nordea's confidence in ResMed's long-term growth potential due to increasing demand for its sleep apnea and respiratory care devices. ResMed's market-leading position makes it an attractive investment for major institutional investors.

https://nationaltoday.com/us/ca/san-diego/news/2026/03/22/nordea-investment-management-boosts-resmed-stake-by-37/

ResMed Inc. stock advances amid strong Q2 earnings and digital health push, drawing DACH investor in

ResMed Inc. reported strong Q2 FY26 results with an 11% revenue increase to $1.42 billion, driven by demand for CPAP devices and digital health solutions. The company's focus on digital therapeutics, robust financial health, and strong European market penetration are attracting German-speaking (DACH) investors. ResMed's stock performance reflects its resilience and leadership in the sleep apnea and digital health sectors.

https://www.ad-hoc-news.de/boerse/news/ueberblick/resmed-inc-stock-advances-amid-strong-q2-earnings-and-digital-health/68948726

LivaNova aura6000 Obstructive Sleep Apnea treatment granted FDA premarket approval

LivaNova's aura6000 System, designed for treating moderate to severe Obstructive Sleep Apnea (OSA) using proximal hypoglossal nerve stimulation (p-HGNS), has received premarket approval (PMA) from the FDA. This approval is supported by data from the OSPREY randomized controlled trial, which demonstrated significant reductions in AHI and ODI. LivaNova plans to introduce a next-generation device with MRI compatibility, remote configuration, and an extended battery life.

https://med-techinsights.com/2026/03/20/livanova-aura6000-obstructive-sleep-apnea-treatment-granted-fda-premarket-approval/

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.8% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.2% Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.2% Today

Wingstop Inc. ($WING) Stock Forecast: Down 5.6% Today

Five Below Inc. ($FIVE) Stock Forecast: Down 5.4% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Down 5.8% Today

Silver ($XAG) Commodity Forecast: Down 5.0% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

Teleflex Incorporated ($TFX) Stock Forecast: Down 5.1% Today

ResMed Inc. Price History

30.00.2026 - RMD Stock was down 0.8%

• The strong bearish movement in ResMed's stock today could be attributed to profit-taking by investors after a period of positive performance and price appreciation.
• Despite the impressive Q2 results and increased institutional interest in the company's stock, the notable insider selling by CEO Michael J. Farrell and others might have raised concerns among investors about the future outlook of the company.
• Additionally, the market may be reacting to the Hold rating reiterated by an independent analyst, indicating a more cautious stance on the stock despite the positive financial performance.
• Overall, the bearish movement could be a result of a combination of factors, including profit-taking, insider selling, and cautious analyst sentiment, leading to a temporary dip in the stock price.

13.00.2026 - RMD Stock was down 0.3%

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

05.00.2026 - RMD Stock was up 1.3%

• The significant insider selling and institutional ownership of ResMed Inc. could have initially raised concerns among investors, but the company's ability to surpass EPS and revenue expectations likely reassured the market.
• ResMed's strategic shift towards a connected ecosystem for sleep and respiratory care may have sparked investor optimism about the company's long-term growth potential and competitive edge.
• The high institutional ownership, particularly with influential shareholders like The Vanguard Group, Inc., suggests a level of confidence in ResMed's future performance, potentially contributing to the bullish movement in the stock.
• Overall, the combination of positive financial results, strategic positioning in the market, and strong institutional support likely drove the bullish momentum in ResMed's stock today.

24.03.2025 - RMD Stock was up 5.1%

• ResMed reported stellar third-quarter fiscal 2025 results, surpassing earnings and revenue estimates, showcasing strong execution across all business areas.
• The appointment of Salli Schwartz as Chief Investor Relations Officer could have instilled confidence in investors, signaling a focus on transparent communication and investor relations.
• The positive market reaction indicates that investors are optimistic about ResMed's future prospects and growth trajectory, driven by robust financial performance and strategic leadership appointments.

31.09.2025 - RMD Stock was down 6.1%

• Despite ResMed (RMD) beating earnings and revenue estimates for Q1, the stock experienced a bearish movement.
• The options market activity suggests that there might be some uncertainty or negative sentiment surrounding the stock.
• Investors may be reacting to factors beyond the quarterly performance, such as future growth projections or market conditions.
• The bearish movement could also be influenced by profit-taking activities following a period of positive performance.

04.01.2026 - RMD Stock was up 2.6%

• Institutional investors acquiring significant stakes in ResMed Inc. indicate growing confidence in the company's future prospects, contributing to the bullish movement.
• Despite insider selling trends, the positive quarterly results and dividend announcement have likely boosted investor sentiment towards ResMed.
• Emphasizing ResMed as a stable long-term investment in the healthcare sector reinforces the positive market movement, attracting more investors to the stock.
• The overall bullish sentiment towards ResMed is further supported by the insider sell alert, which, despite the selling activity, did not deter investors, possibly due to the company's strong fundamentals and growth potential.

08.03.2025 - RMD Stock was down 5.1%

• ResMed recently introduced NightOwl, an FDA-approved home sleep apnea test in the US. Nevertheless, the stock faced a decline in the market.
• Speculation from sources suggests the stock may not see further growth despite positive earnings estimate revisions.
• Investor expectations for ResMed's performance could have driven a sell-off of the stock following news of the successful product launch.

04.07.2025 - RMD Stock was up 4.0%

• ResMed (RMD) exceeded expectations in Q2 earnings, outperforming projections for both earnings per share and sales.
• Analysts have raised their forecasts for the company following the strong earnings report, signaling confidence in its future performance.
• Surpassing estimates for Q4 earnings and revenue reinforces ResMed's market position and indicates potential for further growth.
• The uptick in ResMed's stock price reflects its robust financial results and positive outlook for the future.

25.02.2026 - RMD Stock was down 3.2%

• A downgrade from Buy to Hold may have influenced investor sentiment, leading to a sell-off of ResMed's shares.
• Despite maintaining a Buy rating and a positive outlook, the market might have reacted more strongly to the rating change.
• An increased stake by Nordea Investment Management indicates long-term confidence in ResMed but short-term market dynamics could have overshadowed this positive development.
• The FDA approval of LivaNova's aura6000 System for OSA treatment may have created some competition concerns among investors, impacting ResMed's stock performance negatively.

11.01.2026 - RMD Stock was down 6.1%

• Significant selling activity by Baader Bank Aktiengesellschaft and CEO Michael Farrell, reducing their stakes in ResMed, might have signaled a lack of confidence in the company's future performance, contributing to the bearish trend.
• Despite ResMed's strong quarterly results and analyst recommendations, insider selling totaling over $4.6 million could have raised concerns among investors about the company's growth potential.
• The high institutional ownership of 73% in ResMed indicates that any changes in their positions could heavily influence the stock price, potentially leading to a bearish sentiment as seen today.
• A comparison with Ross Stores in discussions about market interest highlights the contrasting performance and market perception between the two companies, potentially leading investors to shift their focus away from ResMed, contributing to the bearish movement.

12.01.2026 - RMD Stock was down 5.1%

• The stock's decline could be linked to CEO Michael Farrell selling a significant number of shares, leading to investor concerns regarding the company's future.
• The reduction in ResMed's stake by Baader Bank Aktiengesellschaft may have also fueled negative sentiment, despite the company surpassing quarterly expectations.
• Market reaction to the ongoing clinical trial of ResMed's new software tool for sleep apnea patients might be influencing investor decisions, awaiting substantial results.
• Insider selling, institutional adjustments, and trial progress are potential factors contributing to today's bearish movement in ResMed's stock.

07.03.2025 - RMD Stock was up 5.7%

• Resmed's stock saw a rise following the successful launch of NightOwl, a home sleep apnea test, in the US.
• The FDA-cleared diagnostic tool is expected to boost the company's market presence and revenue prospects in the sleep apnea sector.
• Investor reactions indicate faith in Resmed's cutting-edge products and its capacity to meet the increasing need for in-home healthcare remedies.